Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
ConclusionsThis model confirms the Bellmunt model with the addition of NLR > 3 and GFR less than 60 ml/min and can be associated with clinical trials that use immunotherapy in patients with bladder cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Hepatocellular Carcinoma | Immunotherapy | Laboratory Medicine | Liver | Liver Cancer | Statistics | Study | Urology & Nephrology